A twelve week, open-label, randomised, parallel-group study evaluating safety, tolerability and pharmacokinetics (PK) of oral nintedanib in combination with oral pirfenidone, compared to treatment with nintedanib alone, in patients with idiopathic pulmonary fibrosis (IPF)

Trial Profile

A twelve week, open-label, randomised, parallel-group study evaluating safety, tolerability and pharmacokinetics (PK) of oral nintedanib in combination with oral pirfenidone, compared to treatment with nintedanib alone, in patients with idiopathic pulmonary fibrosis (IPF)

Completed
Phase of Trial: Phase IV

Latest Information Update: 12 Oct 2017

At a glance

  • Drugs Nintedanib (Primary) ; Pirfenidone
  • Indications Idiopathic pulmonary fibrosis
  • Focus Adverse reactions
  • Acronyms INJOURNEY
  • Sponsors Boehringer Ingelheim
  • Most Recent Events

    • 11 Sep 2017 According to a Boehringer Ingelheim Media Release, results from this trial published in the American Journal of Respiratory and Critical Care Medicine.
    • 11 Sep 2017 Results published in the Boehringer Ingelheim Media Release
    • 10 Sep 2017 Results published in the American Journal of Respiratory and Critical Care Medicine
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top